US Patent Issued to GENENTECH, NATIONAL CANCER CENTER, VENTANA MEDICAL SYSTEMS on Feb. 3 for "HER2 heterogeneity as a biomarker in cancer" (American, Japanese Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,359, issued on Feb. 3, was assigned to GENENTECH INC. (South San Francisco, Calif.), NATIONAL CANCER CENTER (Tokyo) and VENTANA MEDICAL SYSTEMS INC. (Tucson, Ariz.).

"HER2 heterogeneity as a biomarker in cancer" was invented by Adrian E. Murillo (Tucson, Ariz.), Hiro Nitta (Tucson, Ariz.), Donald G. Munroe (Tucson, Ariz.), Amy A. Lo (San Francisco), Takeshi Kuwata (Kashiwa, Japan), Akio Kaito (Kashiwa, Japan) and Atsushi Ochiai (Kashiwa, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method for predicting responsiveness to a HER2-directed therapy by assessing HER2 heterogeneity in a tumor includes contacting a sample of the tumor with a bioma...